The therapy offers a promising new approach to tackling the growing challenge of antimicrobial resistance, said the study published in the international UK medical journal The Lancet Infectious Diseases in late September.

China: New Drug Used to Treat Common Infection! (19.11.2025)

A new treatment combination for Helicobacter pylori — a common stomach bacterium linked to ulcers and gastritis — based on a domestically developed drug has shown comparable, and in some cases superior, efficacy in eradicating the infection compared with standard therapy, according to recent clinical research.

The therapy offers a promising new approach to tackling the growing challenge of antimicrobial resistance, said the study published in the international journal The Lancet Infectious Diseases in late September.

The experimental triple therapy centres on rifasutenizol, a novel antimicrobial agent developed specifically for H. pylori infection by Tennor Therapeutics, a pharmaceutical company based in Suzhou, Jiangsu province.

PRC: Mainland Student Group Arrives in Taiwan Region! (17.7.2023)

The trip is scheduled to include stops in Taipei, Taichung, New Taipei, Hsinchu and Hualien.

On Saturday evening, Ma Ying-jeou held a dinner reception to welcome the group. He said the visit is the most important event to boost exchanges between young people on both sides in recent years.

He also expressed his hope that cross-Strait tensions could be eased and cross-Strait exchanges fully resumed to benefit people on both sides.

Between late March and early April this year, Ma took a group of Taiwan students to the mainland and had discussions at three universities, during which he repeatedly expressed his hope that teachers and students from mainland universities could visit Taiwan on an exchange basis.